Quiz: Role of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma
How knowledgeable are you about the use of proteasome inhibitors in relapsed/refractory multiple myeloma? Take our latest quiz to find out. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2019 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Two US cancer patients treated with controversial CRISPR technology
Scientists at the University of Pennsylvania have edited the genes of two adult patients with sarcoma and myeloma using the controversial CRISPR technology, a spokesperson told NPR. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2019 Category: Consumer Health News Source Type: news

Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study. (Source: The Scientist)
Source: The Scientist - April 16, 2019 Category: Science Tags: News & Opinion Source Type: news

Combination Therapy Enhances Stem Cell Mobilization in Patients With Multiple Myeloma
A phase III trial evaluated intermediate-dose cytarabine plus  granulocyte-colony stimulating factor (G-CSF) vs G-CSF alone prior to autoSCT in multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck, PhD Source Type: news

CD38-Targeting Isatuximab Combo Active in Refractory Myeloma
Researchers tested the combination of isatuximab with dexamethasone and pomalidomide in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Specific criteria needed for different types of myeloma
(Medical College of Georgia at Augusta University) When our plasma cells start producing a single cancer-causing protein rather than an array of antibody-like proteins to protect us, it's one of two arms of the Y-shaped protein that's likely to blame. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2019 Category: International Medicine & Public Health Source Type: news

New CAR T-Cell Therapy for Multiple Myeloma Targets GPRC5D
Researchers have identified a potential new target for CAR T-cell therapy in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Myeloma Patients Could Self-Administer Bortezomib at Home Myeloma Patients Could Self-Administer Bortezomib at Home
Multiple myeloma patients or even their relatives can be taught to safely self-administer bortezomib at home, reducing both the time they spend at the clinic and resource use, say UK researchers.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Single agent umbralisib effective for relapsed slow-growing lymphoma
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma& Myeloma, at the AACR Annual Meeting 2019 in Atlanta. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Denosumab cost effective in patients with multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2019 Category: Drugs & Pharmacology Source Type: news

Do water bottles cause cancer? Expert fact-checks the thriving myth fueled by Tom Brokaw
The 79-year-old anchor, who has multiple myeloma, said he does not drink out of plastic water bottles anymore after a 'leading cancer researcher' suggested they are linked to cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - March 26, 2019 Category: Consumer Health News Source Type: news

FDA Scrambles to Prevent Shortages Amid Sterilization Shutdowns
Shutdowns of two facilities that use ethylene oxide to sterilize medical devices have raised concern about potential shortages in the medtech industry because this is such a popular sterilization method for medical devices. Ethylene oxide (EtO) is a flammable, colorless gas used to make a range of products. EtO also is used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. According to the EPA, long-term exposure to EtO can irritate the eyes,...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Tom Brokaw, 79, reveals he takes medical marijuana to relieve his pain after beating blood cancer
The 79-year-old newscaster, known for being straight-laced, revealed on Tuesday that he turned to the drug to ease his pain from multiple myeloma, a type of blood cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - March 26, 2019 Category: Consumer Health News Source Type: news

Janssen Submits Application for DARZALEX ® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 26, 2019 Category: Pharmaceuticals Source Type: news

Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy - Um ıt EG, Baysal M, Bas V, Asker I, Kırkızlar O, Demır AM.
PURPOSE: Multiple myeloma is a chronic, uncurable hematological cancer with the involvement of multiple organ systems. As a disease affecting older patients, the treatment of multiple myeloma should be based on individual patient characteristics. Polypharm... (Source: SafetyLit)
Source: SafetyLit - March 24, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

FDA: Higher Risk for Death Found With Venclexta in Multiple Myeloma
FRIDAY, March 22, 2019 -- A safety statement was issued yesterday by the U.S. Food and Drug Administration regarding risks found to be associated with the investigational use of Venclexta (venetoclax) for treatment of patients with multiple... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 22, 2019 Category: Pharmaceuticals Source Type: news

Clinical Trials of Venetoclax in Myeloma Stopped Due to Deaths Clinical Trials of Venetoclax in Myeloma Stopped Due to Deaths
The FDA issued a partial hold on all ongoing clinical trials evaluating venetoclax in multiple myeloma because of an excessive number of deaths seen in the BELLINI study.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 21, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Clinical Trials With Venetoclax on Hold Because of Deaths Clinical Trials With Venetoclax on Hold Because of Deaths
The FDA issued a partial hold on all ongoing clinical trials evaluating venetoclax in multiple myeloma because of an excessive number of deaths seen in the BELLINI study.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 21, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Recommendations Issued for HSCT in Multiple Myeloma
WEDNESDAY, March 20, 2019 -- A consensus statement for the use of hematopoietic stem cell transplantation (HSCT) in the treatment of multiple myeloma (MM) has been developed by Mayo Clinic physicians; the recommendations were published in the March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news

Model Predicts Survival in Transplant - Ineligible Myeloma Patients
U.K. Myeloma Research Alliance Risk Profile predicts overall survival based on data from two trials (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 20, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Model Predicts Survival in Transplant-Ineligible Myeloma Patients
TUESDAY, March 19, 2019 -- For patients with multiple myeloma who are ineligible for stem cell transplantation, a risk profile can predict overall survival, according to a study recently published in The Lancet Haematology. Gordon Cook, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2019 Category: Pharmaceuticals Source Type: news

FDA puts partial hold on clinical trials of AbbVie's cancer drug
AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation
An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2019 Category: Cancer & Oncology Authors: Kevin H. Hall, PharmD, BCOP Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX ® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 12, 2019 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab vs IV Formulation in Relapsed Multiple Myeloma
The phase III COLUMBA study compared a subcutaneous formulation of daratumumab vs the intravenous form in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Residual Disease May Predict Multiple Myeloma Prognosis Residual Disease May Predict Multiple Myeloma Prognosis
Measuring minimal residual disease before, during, or after transplant may offer useful prognostic information for multiple myeloma patients, say US scientists.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Quiz: Recognizing Comorbidities in Multiple Myeloma Patients
Are you aware of the common comorbidities seen in patients with multiple myeloma? Take our latest quiz to test your knowledge. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2019 Category: Cancer & Oncology Source Type: news

Kaiku Health partners with Amgen to roll out digital symptom tracking for multiple myeloma
Amgen Finland Country Director Niilo F ärkkilä said Finland was " an excellent testbed for novel solutions like Kaiku Health " . (Source: mobihealthnews)
Source: mobihealthnews - March 4, 2019 Category: Information Technology Source Type: news

Ex-Myeloma Unit Chief Gareth Morgan Says UAMS Audit Faulted Accounting
Dr. Gareth Morgan, former director of the Myeloma Institute for Research & Therapy at the University of Arkansas for Medical Sciences in Little Rock, said $29 million in operating losses detected by a recent audit were “accounting errors” outside his control. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - March 4, 2019 Category: American Health Source Type: news

Scoring System Could Guide Decisions in Transplant-Ineligible Myeloma
Researchers have developed and validated a clinical scoring system that could help guide treatment decisions among patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - March 1, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Comparing treatment costs for multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2019 Category: Drugs & Pharmacology Source Type: news

Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 27, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Panel Punts on Selinexor for Multiple Myeloma
(MedPage Today) -- Majority say approval decision should wait for ongoing trial results (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 26, 2019 Category: American Health Source Type: news

Ixazomib Shows Promise as Option for Chronic GVHD Ixazomib Shows Promise as Option for Chronic GVHD
Patients with advanced chronic graft versus host disease who have failed multiple therapies may respond to ixazomib, a drug approved for second-line multiple myeloma treatment, say US scientists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Patient Deaths, Efficacy Data May Sink Myeloma Drug at FDA Panel
(MedPage Today) -- Committee to vote whether approval decision should wait on further data (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 25, 2019 Category: American Health Source Type: news

Accounting Maneuvers Hid Funding Failures at UAMS
When the University of Arkansas for Medical Sciences announced in April 2014 that Dr. Gareth Morgan would lead the Myeloma Institute for Research & Therapy, it was cause for a celebration. The cheers didn’t last long. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - February 25, 2019 Category: American Health Source Type: news

Risk Profile Predicts Survival in Transplant-Ineligible Multiple Myeloma Risk Profile Predicts Survival in Transplant-Ineligible Multiple Myeloma
In patients with multiple myeloma who are ineligible for stem-cell transplantation, the UK Myeloma Research Alliance Risk Profile (MRP) predicts overall survival across treatments and genetic factors, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Lenalidomide Maintenance vs Observation For Newly Diagnosed Myeloma
Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Second AHCT, RVD Consolidation Post-AHCT Intervention in Myeloma?
A study investigates the efficacy of a second AHCT or RVD consolidation post-AHCT intervention in transplantation-eligible myeloma patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

HRQoL Scores Decrease With Treatment Line in Multiple Myeloma
Relatively high scores seen for patients with multiple myeloma in first treatment - free interval (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 13, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

HRQoL Scores Decrease With Treatment Line in Multiple Myeloma
WEDNESDAY, Feb. 13, 2019 -- For patients with multiple myeloma (MM), health-related quality of life (HRQoL) scores decrease with treatment line, according to a study published in the January issue of Clinical Lymphoma, Myeloma&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

4 Important Steps to Take After a Cancer Diagnosis
Each year, more than 1.7 million people in the United States hear three dreaded words: You have cancer. As common as cancer is, no one expects cancer to happen to them. We understand, as patients and as caregivers, how frightening a cancer diagnosis can be: how it can upend your life, leaving you feeling like you’re barely treading water. And we know that making tough decisions when your life depends on it is not easy. From our research at Harvard Business School of how people navigate their cancer treatment (and what they wish they had known sooner), we have developed four steps that all people with cancer can take ...
Source: TIME: Health - February 12, 2019 Category: Consumer Health News Authors: Kathy Giusti and Lori Tauber Marcus Tags: Uncategorized Cancer Source Type: news

U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Revised product label allows for new administration option HORSHAM, Pa., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FD... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

AbbVie, Teneobio partner on Multiple Myeloma
AbbVie and Teneobio announced a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 11, 2019 Category: Pharmaceuticals Source Type: news

Obesity-Linked Cancers On the Rise in Young Adults
In the study, the cancer incidence increases were particularly severe in six of the 12 obesity-related cancers: colon, uterine, gallbladder, kidney and pancreas, and multiple myeloma -- a bone marrow cancer. (Source: WebMD Health)
Source: WebMD Health - February 4, 2019 Category: Consumer Health News Source Type: news

Millennials Getting More Obesity-Related Cancers, Study Finds
This study shows the incidence of cancer associated with obesity has been rising dramatically in groups of individuals born in more recent decades,” said MD Anderson Cancer Center’s Dr. George Chang, who was not associated with the analysis. However, Chang warns against overgeneralizing on the basis of an epidemiological study. “The study was not set up to establish causation,” Chang said. “We know there are many factors that are associated with both obesity and cancer, such as lack of exercise and poor diet. How much each of those factors contribute to cancer is less clear.” Obesity is ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Cancer CNN Millennials Source Type: news

Some Cancers Are Rising in Young People. Scientists Think They Know Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endom...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be the Reason Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35. Rates ...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35. Rates ...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news